Arcus Biosciences RCUS Debt - Unamortized Discount (Premium) and Issuance Costs, Net
Debt - Unamortized Discount (Premium) and Issuance Costs, Net at other companies
Other financials
Where this comes from
Reported directly by Arcus Biosciences in its filing.
Tagged under the XBRL concept us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet.
The official record: Arcus Biosciences’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Arcus Biosciences's debt - unamortized discount (premium) and issuance costs, net.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI

Claude
Questions, answered.
- What is Arcus Biosciences's debt - unamortized discount (premium) and issuance costs, net?
- Arcus Biosciences (RCUS) reported debt - unamortized discount (premium) and issuance costs, net of $0 in Q1 2026.
- How has Arcus Biosciences's debt - unamortized discount (premium) and issuance costs, net changed year-over-year?
- Arcus Biosciences's debt - unamortized discount (premium) and issuance costs, net decreased by 100.0% year-over-year, from $2M to $0.
- What does debt - unamortized discount (premium) and issuance costs, net mean?
- This represents the net adjustment to the face value of debt, accounting for original issue discounts, premiums, and capitalized debt issuance costs. These amounts are amortized over the life of the debt instrument to reflect the effective interest rate. It is essential for reconciling the carrying value of debt to its face value.